Abstract: Pancreatic adenocarcinoma is a highly lethal disease with a high morbidity and dismal prognosis. A multidisciplinary consultation based on evidence based medicine has become the main modality for treatment of pancreatic adenocarcinoma. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology has been widely recognized and implemented. Recently,the guidelines (version 1. 2017) in oncology have been published by NCCN. This article will summarize and interpret the updates of the new version of the NCCN guideline for pancreatic adenocarcinoma.